Portal de Periódicos da CAPES

Rationale and Design of ATHENA: A Placebo‐Controlled, Double‐Blind, Parallel Arm T rial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular H ospitalization or Death from Any Cause in Pati EN ts with A trial Fibrillation/Atrial Flutter

2007; Wiley; Volume: 19; Issue: 1 Linguagem: Inglês

10.1111/j.1540-8167.2007.01016.x

1540-8167

Stefan H. Hohnloser, Stuart J. Connolly, Harry J.G.M. Crijns, Richard L. Page, Werner Seiz, Christian Torp-Petersen,

Cardiac electrophysiology and arrhythmias

Background: Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia, predominantly affecting elderly patients. There is a continued need for new antiarrhythmic drugs to treat the ever‐increasing number of patients with this arrhythmia. Dronedarone is a new antiarrhythmic compound currently being developed for treatment of AF. Methods: The ATHENA trial ( A placebo‐controlled, double‐blind, parallel arm T rial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular H ospitalization or death from any cause in pati EN ts with A trial fibrillation/atrial flutter) is the largest single antiarrhythmic drug trial ever conducted. More than 4,600 patients with a history of AF or atrial flutter (AFL) have been randomized to receive dronedarone 400 mg bid or matching placebo. The primary study endpoint is time to first cardiovascular hospitalization or death from any cause. The study has completed patient enrollment in December 2006 and is expected to end follow‐up 1 year later. Conclusion: ATHENA will be the largest efficacy and safety trial of dronedarone, a multichannel blocker compound with properties from class I, II, III, and IV antiarrhythmic drugs developed to treat patients with AF.